Alzheimer’s roundup: Clinical progress and setbacks at CTAD

The latest data from Roche’s Phase Ib/IIa study of trontinemab suggest the pharma’s brainshuttle technology is doing its job. 

The brainshuttle-enabled anti-amyloid mAb, concentrates in the CNS via active transport, appears on track to achieve the goal of accelerating β-amyloid plaque clearance and simultaneously decreasing the drug class’ most troublesome safety risks, brain swelling and hemorrhage...